Welcome to our dedicated page for Zentalis Pharmaceuticals news (Ticker: ZNTL), a resource for investors and traders seeking the latest updates and insights on Zentalis Pharmaceuticals stock.
Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative small molecule therapeutics that target fundamental biological pathways in cancer. Utilizing its proprietary Integrated Discovery Engine, Zentalis aims to identify unique targets and develop novel, potentially best-in-class new chemical entities (NCEs) with differentiated product profiles.
The company's robust pipeline is highlighted by two lead product candidates: ZN-c5 and ZN-c3. ZN-c5 is being developed for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer, while ZN-c3 targets advanced solid tumors and ovarian cancer. Zentalis is also developing azenosertib (ZN-c3), a WEE1 inhibitor, as a monotherapy and in combination with other agents to address multiple tumor types.
Recently, Zentalis announced plans to use the net proceeds from its latest offering to fund ongoing and planned clinical trials, as well as for working capital and other general corporate purposes. The company’s financial strategy is designed to support its operational expenses and capital expenditure requirements through 2026.
The company’s latest financial disclosures highlighted strong clinical data for azenosertib, showing an objective response rate of 36.8% in ovarian cancer and uterine serous carcinoma patients. Azenosertib, currently in multiple clinical trials, demonstrated encouraging efficacy both as a monotherapy and in combination with chemotherapy.
Headquartered in New York and San Diego, Zentalis is collaborating with top financial institutions like Morgan Stanley, Jefferies, and Guggenheim Securities to drive its growth. The company's strong cash position is bolstered by its recent offerings and ongoing support from financial advisors.
Continuing to advance its clinical strategies, Zentalis is focused on its fast-to-market approach for azenosertib, aiming to submit its first NDA in gynecologic malignancies by 2026. Furthermore, Zentalis is leveraging its expertise in cancer biology and medicinal chemistry to explore the potential of protein degraders and other innovative treatment modalities.
Stay updated on Zentalis Pharmaceuticals’ latest developments by visiting their official website or following them on social media platforms such as Twitter and LinkedIn.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) reported financial results for Q3 2021, revealing a net loss of $10.5 million, significantly lower than the $34.7 million loss in Q3 2020. The company initiated a Phase 1/2 trial for ZN-c3 combined with gemcitabine in osteosarcoma and is progressing in a Phase 2 trial for uterine serous carcinoma. As of September 30, 2021, Zentalis holds $366.8 million in cash, expected to sustain operations through Q3 2023. Research and development expenses increased to $54 million, reflecting enhanced clinical activities.
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) has announced that CEO Anthony Sun will present at two upcoming investor conferences. The Stifel 2021 Virtual Healthcare Conference is scheduled for November 17, 2021, at 8:40 a.m. EST, while the Jefferies London Healthcare Conference will be available on-demand starting November 18, 2021, at 8:00 a.m. GMT. Webcasts for these presentations will be accessible via the company’s website. Zentalis focuses on developing small molecule therapeutics for cancer treatment.
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) has initiated a Phase 1/2 trial for ZN-c3, an oral WEE1 inhibitor, in combination with gemcitabine for treating relapsed or refractory osteosarcoma. The trial aims to evaluate clinical safety and efficacy, with initial results expected in the second half of 2022. Zentalis has received orphan drug and rare pediatric disease designations from the FDA for this indication, potentially leading to a priority voucher upon approval. Osteosarcoma, primarily affecting younger patients, has a poor prognosis, highlighting the urgent need for effective therapies.
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) has announced the acceptance of six abstracts for poster presentation at the European Society for Medical Oncology (ESMO) Congress, taking place virtually from September 16-21, 2021. Highlights include studies on ZN-c3, a WEE1 inhibitor, and ZN-c5, an oral selective estrogen receptor degrader, targeting advanced cancers. The posters will be accessible on the Congress platform starting September 16 at 8:30 a.m. CEST and will also appear on Zentalis' website.
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) announced participation in two virtual investor conferences. The Morgan Stanley Global Healthcare Conference is on September 10, 2021, at 2:45 p.m. EDT, featuring a live fireside chat with CEO Anthony Sun. The H.C. Wainwright Global Life Sciences Conference follows on September 13, 2021, at 7:00 a.m. EDT, presented on demand. Webcasts will be available on the company’s website, showcasing Zentalis's focus on developing small molecule therapeutics for cancer.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced the publication of its WEE1 inhibitor candidate, ZN-c3, in the Journal of Medicinal Chemistry. This selective WEE1 inhibitor aims to enhance cancer treatment efficacy by targeting the cell cycle regulator WEE1. ZN-c3 is under evaluation in multiple trials, including potential accelerated approval routes for uterine serous carcinoma. The company believes ZN-c3's profile may represent a best-in-class oncology treatment, following promising clinical results reported in June.
Zentalis Pharmaceuticals (ZNTL) reported promising new data for ZN-c3 and ZN-c5, highlighting their potential as best-in-class cancer therapies. The company successfully dosed the first patient in a Phase 2 trial for ZN-c3 targeting uterine serous carcinoma (USC). Additionally, Zentalis raised approximately $173 million in a public offering to support future milestones. The second quarter of 2021 saw a net loss of $55.1 million, driven by increased R&D expenses. As of June 30, 2021, Zentalis held $250.9 million in cash, which is expected to fund operations well into Q3 2023.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced that CEO Anthony Sun will participate in a panel discussion at the Wedbush PacGrow Healthcare Virtual Conference on August 11, 2021, at 10:20 a.m. ET. The event will be accessible via a live webcast on the company’s website. Zentalis focuses on developing small molecule therapeutics for cancer, with a pipeline including candidates like ZN-c3 and ZN-c5 targeting various tumors. The company operates in New York and San Diego.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced the dosing of the first patient in a Phase 2 trial for ZN-c3, an oral WEE1 inhibitor, targeting recurrent uterine serous carcinoma (USC). The FDA indicated that ZN-c3 may pursue an accelerated approval pathway based on the trial's design. This Phase 2 trial aims to evaluate the drug's clinical activity, safety, and pharmacokinetics. USC has a poor prognosis, with survival rates of only 30-50%, highlighting the urgent need for effective therapies. ZN-c3 is positioned as a potentially first-in-class treatment, which could redefine USC care.
Zentera Therapeutics has successfully completed a $75 million Series B financing, led by OrbiMed Advisors Asia and Tybourne Capital Management. The funds will support the clinical development of three oncology candidates from Zentalis Pharmaceuticals (Nasdaq: ZNTL) in China, including WEE1 inhibitor ZN-c3, oral SERD ZN-c5, and BCL-2 inhibitor ZN-d5. Zentera has received four Clinical Trial Applications approved in China and aims to advance its pipeline further. The leadership team expresses confidence in becoming a leading biopharmaceutical company focused on delivering innovative cancer therapies.
FAQ
What is the current stock price of Zentalis Pharmaceuticals (ZNTL)?
What is the market cap of Zentalis Pharmaceuticals (ZNTL)?
What products is Zentalis Pharmaceuticals currently developing?
What is the purpose of Zentalis Pharmaceuticals' recent financial offering?
What is azenosertib and why is it significant?
Where are Zentalis Pharmaceuticals' main operations located?
Who are Zentalis Pharmaceuticals' financial collaborators?
What is Zentalis’ Integrated Discovery Engine?
When does Zentalis plan to submit its first NDA for azenosertib?
What are the recent clinical achievements of Zentalis Pharmaceuticals?
How does Zentalis plan to use its expertise in cancer biology?
Where can one access more information about Zentalis Pharmaceuticals?
